Cellectar Biosciences, Inc. CLRB
1.80
(0.28)
(13.46%)
as of 25 Sep
- Market cap
- $19.6M
- P/E
- 0.0×
Follow CLRB
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
2.77 | 2.96 | 1.90 | 6.66 |
Net Debt/EBITDA |
2.55 | 2.34 | 1.41 | 4.75 | |
Debt/Assets |
2.30% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.04 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.96 | 0.82 | 0.86 | 0.87 | |
Capex/Depreciation |
0.00 | (0.12) | 0.03 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(1.35) | (1.67) | (1.14) | (0.49) | |
Cash per Share |
3.97 | 5.06 | 1.97 | 2.78 | |
Shareholders Equity per Share |
2.53 | 3.27 | 0.79 | 2.44 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.53 | 3.27 | 0.79 | 2.44 | |
Free Cash Flow |
(4.28) | (4.35) | (4.85) | (6.01) | |
Working Capital |
8.71 | 9.29 | 4.39 | 29.64 | |
Capital Expenditures |
— | (0.01) | 0.00 | 0.00 | |
Net Current Asset Value |
6.99 | 7.60 | 1.48 | 28.11 | |
| Other line items | |||||
Quick Ratio |
2.56 | 2.78 | 1.71 | 6.49 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.35) | (1.67) | (1.14) | (0.49) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
6.16 | 6.00 | 4.30 | 4.95 | |
Average Assets |
25.96 | 20.23 | 13.58 | 25.17 | |
Average Common Equity |
4.51 | 10.90 | 5.27 | 17.72 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates